The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunology
• Thoracic Surgery

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
• Immunotherapy, particularly anti-PD-1/PD-L1 checkpoint inhibitors, has significantly improved outcomes in advanced NSCLC.
• These therapies are increasingly used in the perioperative setting for early-stage NSCLC.

Purpose of the Study:

• To review current therapeutic targets within the NSCLC tumor microenvironment (TME).
• To discuss the impact and future directions of immunotherapy in NSCLC.
• To explore how TME-specific target investigations may influence thoracic surgical care.

Main Methods:

• Review of current literature on NSCLC tumor microenvironment and immunotherapy.
• Analysis of clinical advancements and future therapeutic strategies.
• Discussion of the implications for thoracic surgery.

Main Results:

• Immunotherapy has transformed NSCLC treatment, improving survival in advanced disease.
• The NSCLC TME offers numerous potential targets for novel therapeutic strategies.
• Investigating TME-specific targets is crucial for advancing NSCLC care, including surgical management.

Conclusions:

• Targeting the NSCLC TME, especially with immunotherapy, represents a paradigm shift in cancer treatment.
• Continued research into TME-specific targets is essential for developing more effective therapies.
• Understanding TME dynamics is critical for optimizing the role of thoracic surgery in NSCLC management.